Sorafenib
Active ingredient: Sorafenib
In short: Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iod
What is Sorafenib used for?
Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
Sorafenib dosage
The recommended dosage of sorafenib tablets is 400 mg orallytwice daily without food (at least 1 hourbefore or 2 hours after a meal) until the patient is no longer clinically benfiting from therapy or until unacceptable toxicity.
Recommended Dosage Modifications
The recommended dosage modifications for adverse reactions are provided in Tables 1, 2, and 3.
Table 1: Recommended Dose Reductions forAdverse Reactions
Dose Reduction | Hepatocellular Carcinoma | Differentiated Thyroid
Carcinoma
First Dose Reduction | 400 mg orally once daily | 400 mg orally in the
morning and 200 mg orally in the evening about 12 hours apart
OR
200 mg orally in the
morning and 400 mg orally in the evening about 12 hours apart
Second Dose Reduction | 200 mg orally once daily
OR
400 every other day | 200 mg orally twice daily
Third Dose Reduction | None | 200 mg orally once daily
Table 2: Recommended Dosage Modifications of Sorafenib Tablets for Adverse Reactions
Adverse Reaction | Severity
1 | Sorafenib
T
ablets Dosage
M
odification
Cardiovascular Events
Cardiac Ischemia and/or
Infarction | Grade 2 and above | Permanently discontinue.
Congestive Heart Failure | Grade 3 | Interrupt2 until Grade 1 or
less, resume at reduced dose by 1 dose level.3
Grade 4 | Permanently discontinue.
Hemorrhage
| Grade 2 and above requiring medical
intervention | Permanently discontinue.
Hypertension
| Grade 2 (symptomatic/persistent)
OR
Grade 2 symptomatic increase by greater than 20 mm Hg (diastolic) or greater than 140/90 mm Hg if previously within normal limits
OR
Grade 3 | Interrupt until symptoms
resolve and diastolic blood pressure less than 90 mm Hg, then resume at reduced dose by 1 dose level.3
If needed, reduce another dose level.3
Grade 4 | Permanently discontinue.
G
astrointestinal Perforation
| Any grade | Permanently discontinue.
QT Interval Prolongation
| Greater than 500 milliseconds
OR
Increase from baseline of 60 milliseconds or greater | Interrupt and correct
electrolyte abnormalities (magnesium, potassium, calcium).
Use medical judgement before restarting.
Drug-Induced Liver Injury
| Grade 3 ALT or higher in the absence of another cause4
OR
AST/ALT greater than 3 Γ upper limit normal (ULN) with bilirubin
greater than 2 Γ ULN in the absence of another cause4 | Permanently discontinue.
Non-hematological toxicities
| Grade 2 | Continue treatment at
reduced dose by 1 dose level.
Grade 3
1st occurrence | Interrupt until Grade 2 or
less, then resume at reduced dose by 1 dose level.
No improvement within 7 days
OR
2nd or 3rd occurrence | Interrupt until Grade 2 or
less, then resume at reduced dose by 2 dose levels.
4th occurrence | Interrupt until Grade 2 or
less, then resume at reduced dose by 2 dose levels for HCC or 3 dose levels for DTC.
Grade 4 | Permanently discontinue. β¦
How to take Sorafenib β instructions & advice from the label
Advise the patient to read FDA-approved patient labeling (Patient Information).
Cardiovascular Events
Discuss with patients that cardiac ischemia and/or infarction and congestive heart failure, have been reported during sorafenib tablets treatment, and that they should immediately report any episodes of chest pain or other symptoms of cardiac ischemia or congestive heart failure .
Bleeding
Inform patients that sorafenib tablets can increase the risk of bleeding and that they should promptly report any episodes of bleeding .
Inform patients that bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on sorafenib tablets and that their INR should be monitored regularly .
Hypertension
Inform patients that hypertension can develop during sorafenib tablets treatment, especially during the first six weeks of therapy, and that blood pressure should be monitored regularly during treatment .
Skin Reactions
Advise patients of the possible occurrence of hand-foot skin reaction and rash during sorafenib tablets treatment and appropriate countermeasures . β¦
Warnings & precautions
Do not take this medicine if: Sorafenib tablets are contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of sorafenib tablets.
Sorafenib tablets in combination with carboplatin and paclitaxel are contraindicated in patients with squamous cell lung cancer .
In the SHARP (HCC) study, the incidence of cardiac ischemia/infarction was 2.7% in sorafenib tablets-treated patients compared with 1.3% in those receiving placebo, and in the DECISION (DTC) study, the incidence of cardiac ischemia/infarction was 1.9% in the sorafenib tablets -treated group compared with 0% in patients receiving placebo. Patients with unstable coronary artery disease or recent myocardial infarction were excluded from this study. In multiple clinical trials, congestive heart failure has been reported in 1.9% of sorafenib tablets - treated patients (N=2276) .
Consider temporary or permanent discontinuation of sorafenib tablets in patients who develop cardiovascular events .
An increased risk of bleeding may occur following sorafenib tablets administration. In the SHARP (HCC) study, the rates of bleeding from esophageal varices (2.4% and 4%) and of bleeding with a fatal outcome from any site (2.4% and 4%) were similar in sorafenib tablets -treated patients and those receiving placebo, respectively. In the DECISION (DTC) study, bleeding was reported in 17.4% of sorafenib tablets -treated patients and 9.6% of those receiving placebo; however, the incidence of Grade 3 bleeding was similar (1% and 1.4%) in sorafenib tablets -treated patients and in those receiving placebo.
If any bleeding necessitates medical intervention, consider permanent discontinuation of sorafenib tablets . Due to the potential risk of bleeding, treat tracheal, bronchial, and esophageal infiltration with local therapy prior to administering sorafenib tablets in patients with DTC. β¦
Sorafenib side effects
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
Cardiovascular events
Hemorrhage
Hypertension
Dermatologic toxicities
Gastrointestinal perforation
QT interval prolongation
Drug-induced liver injury
Impairment of TSH suppression in DTC
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described reflect exposure to sorafenib tablets in 504 patients who participated in placebo-controlled studies in hepatocellular carcinoma N=297), or differentiated thyroid carcinoma (N = 207). The most common adverse reactions (β₯20%), which were considered to be related to sorafenib tablets, in patients with HCC or DTC are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage.
Hepatocellular Carcinoma
Table 4 shows the percentage of patients in the SHARP (HCC) study experiencing adverse reactions that were reported in at least 10% of patients and at a higher rate in the Sorafenib Tablets -treated group than in those eceiving placebo. β¦
Drug interactions
Strong CYP3A4 Inducers
The concomitant use of sorafenib tablets with rifampin, a strong CYP3A4 inducer decreased the mean AUC of sorafenib, which may decrease the antitumor activity . Avoid concomitant use of sorafenib tablets with strong CYP3A4 inducers, when possible, because these drugs can decrease the systemic exposure to sorafenib.
Neomycin
The concomitant use of sorafenib tablets with neomycin decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use of sorafenib tablets with neomycin. The effects of other antibiotics on the pharmacokinetics of sorafenib have not been studied .
The concomitant use of sorafenib tablets and warfarin may increase the risk of bleeding or increased the INR. Monitor INR and for clinical bleeding episodes in patients taking warfarin while receiving sorafenib tablets .
Sorafenib tablets are associated with QTc interval prolongation. Avoid coadministration of sorafenib tablets with medicinal products with a known potential to prolong QT/QTc interval .
No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The pharmacokinetics of sorafenib have not been studied in patients with severe (Child-Pugh C) hepatic impairment .
About this medicine
Sorafenib, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4 methylbenzenesulfonate. The molecular formula of sorafenib tosylate is C21H16ClF3N4O3 x C7H8O3S and the molecular weight of sorafenib tosylate is 637.0 g/mole. Itsβ structural
formula is:
:
Sorafenib tosylate is a white to yellowish or brownish solid. Sorafenib tosylate is practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400.
Sorafenib Tablets, USP for oral use is supplied as film-coated tablets containing 200 mg sorafenib equivalent to 274 mg sorafenib tosylate and the following inactive ingredients: croscarmellose sodium, ferric oxide red, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium lauryl sulphate, and titanium dioxide.
FDA approved dissolution test specifications differ from USP.
How it works: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. β¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID faa9d847-2cd5-6538-e053-6394a90aa92b. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone